- Home
- NEOG vs AUPH Comparison
NEOG vs AUPH Comparison
Compare NEOG & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOG
- AUPH
- Stock Information
- Founded
- NEOG 1981
- AUPH 1993
- Country
- NEOG United States
- AUPH Canada
- Employees
- NEOG N/A
- AUPH N/A
- Industry
- NEOG Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- NEOG Health Care
- AUPH Health Care
- Exchange
- NEOG Nasdaq
- AUPH Nasdaq
- Market Cap
- NEOG 1.3B
- AUPH 1.4B
- IPO Year
- NEOG 1989
- AUPH 1999
- Fundamental
- Price
- NEOG $5.68
- AUPH $11.46
- Analyst Decision
- NEOG Buy
- AUPH Strong Buy
- Analyst Count
- NEOG 4
- AUPH 2
- Target Price
- NEOG $8.33
- AUPH $13.00
- AVG Volume (30 Days)
- NEOG 8.0M
- AUPH 1.9M
- Earning Date
- NEOG 10-09-2025
- AUPH 11-06-2025
- Dividend Yield
- NEOG N/A
- AUPH N/A
- EPS Growth
- NEOG N/A
- AUPH N/A
- EPS
- NEOG N/A
- AUPH 0.42
- Revenue
- NEOG $894,661,000.00
- AUPH $260,111,000.00
- Revenue This Year
- NEOG N/A
- AUPH $17.33
- Revenue Next Year
- NEOG $1.86
- AUPH $14.31
- P/E Ratio
- NEOG N/A
- AUPH $27.86
- Revenue Growth
- NEOG N/A
- AUPH 25.59
- 52 Week Low
- NEOG $3.87
- AUPH $6.55
- 52 Week High
- NEOG $16.79
- AUPH $13.54
- Technical
- Relative Strength Index (RSI)
- NEOG 50.60
- AUPH 47.42
- Support Level
- NEOG $5.55
- AUPH $11.08
- Resistance Level
- NEOG $6.07
- AUPH $11.87
- Average True Range (ATR)
- NEOG 0.28
- AUPH 0.62
- MACD
- NEOG -0.01
- AUPH -0.14
- Stochastic Oscillator
- NEOG 55.38
- AUPH 44.06
About NEOG Neogen Corporation
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.